LOS ANGELES–(BUSINESS WIRE)–The Law Firms of Frank R. Cruz announces an investigation into Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) on behalf of investors regarding the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here participate.
On March 14, 2022, Apyx announced that the United States Food and Drug Administration (“FDA”) would issue a Medical Device Safety Notice (“MDSC”) regarding the company’s advanced energy products. The Company further revealed that “[b]Based on our initial interactions with the FDA, we believe the Agency’s MDSC will relate to the use of our Advanced Energy products outside of their FDA-approved indication for general use in cutting, coagulation, and soft tissue removal during open and laparoscopic surgical procedures. .”
On this news, Apyx’s share price fell $4.02, or 40.6%, to close at $5.88 per share on March 14, 2022, hurting investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you have purchased Apyx securities, have information or want to know more about these claims, or have any questions regarding this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz of the law firm of Lawyers for Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067 at 310-914-5007, by email at [email protected], or visit our website at www.frankcruzlaw.com. If requesting by email, please include your mailing address, phone number and number of shares purchased.
This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.